Previous close | 0.5829 |
Open | 0.0000 |
Bid | 0.0000 x N/A |
Ask | 0.0000 x N/A |
Day's range | 0.0000 - 0.0000 |
52-week range | |
Volume | |
Avg. volume | N/A |
Market cap | 224,788 |
Beta (5Y monthly) | 1.66 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.9620 |
Earnings date | 27 Feb 2023 - 03 Mar 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Zynerba (ZYNE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.